Max Schlaak

Saarland University — Germany

Medicine · Health Sciences

56h-index13.9kcitations529works2.32yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous lymphoproliferative disorders research(59), Cancer Immunotherapy and Biomarkers(57), Cutaneous Melanoma Detection and Management(51), Immunotherapy and Immune Responses(45), Allergic Rhinitis and Sensitization(44)

Publications518 total

Alcian blue‐positive stromal phenotype in basal cell carcinoma is associated with progression on first‐line hedgehog inhibitors

The Journal of Pathology Clinical Research·2026Open Access

Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients

2025Open Access

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

JDDG Journal der Deutschen Dermatologischen Gesellschaft·2025Open Access

Supplementary Table S10 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Data from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Supplementary Table S11 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Supplementary Figure S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Supplementary Table S1 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Supplementary Figure S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Supplementary Figure S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Supplementary Table S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Supplementary Table S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Supplementary Table S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

Supplementary Tables S6-S9 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma

2025Open Access

page 1 of 26Next →

Frequent Co-authors

Lucie Heinzerling(11), Friedegund Meier(10), Joachim Müller‐Quernheim(9), Jochen Utikal(8), Carola Berking(8), Gernot Zissel(7), Markus V. Heppt(7), Axel Hauschild(7), Jessica C. Hassel(6), Wolf‐Meinhard Becker(6), P. Zabel(6), Dirk Schadendorf(6), Bastian Schilling(6), Lisa Zimmer(6), Carmen Loquai(6), Sebastian Haferkamp(5), Sebastian Theurich(5), Ralf Gutzmer(5), Katharina C. Kähler(5), Anja Gesierich(5)